Short-Course Combivir after Single-Dose Nevirapine Reduces but Does Not Eliminate the Emergence of Nevirapine Resistance in Women

Abstract

Background

In the Treatment Options Preservation Study (TOPS) trial, 4 or 7 days of Combivir (CBV; zidovudine/ lamivudine) with maternal single-dose nevirapine (sdNVP) significantly reduced the emergence of NVP resistance as determined by virus population genotyping. To detect NVP resistance with greater sensitivity, we analysed TOPS samples by allele-specific real-time PCR (ASP).

Methods

In a random subset of women from each arm of the trial, plasma samples from before and 6 weeks after sdNVP were analysed using ASP at codons 103, 181, 184 and 190.

Results

Samples were analysed from 27 women in the sdNVP arm and 24 each in the CBV 4-day (sdNVP/ CBV4) and 7-day (sdNVP/CBV7) arms. ASP detected NVP-resistant variants in week 6 samples from 70% of women in the sdNVP arm, 29% in the sdNVP/CBV4 arm and 33% in sdNVP/CBV7 arm (P<0.01 for sdNVP/CBV4 or sdNVP/ CBV7 versus sdNVP; P=1.0 for sdNVP/CBV4 versus sdNVP/ CBV7). Lamivudine resistance was detected by ASP in only 1 of 51 women who received CBV.

Conclusions

Short-course CBV significantly reduced but did not eliminate the emergence of NVP resistance after sdNVP. NVP-resistant variants were detected in about one-third of women despite CBV treatment, but the duration of persistence and clinical impact of these variants in response to antiretroviral therapy is uncertain.

References

Guay

L.A.

, Musoke

, Fleming

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795–802.

Jackson

J.B.

, Musoke

, Fleming

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859–868.

Arrivé

, Dabis

Prophylactic antiretroviral regimens for prevention of mother-to-child transmission of HIV in resource-limited settings. Curr Opin HIV AIDS 2008; 3: 161–165.

Eshleman

S.H.

, Mracna

, Guay

L.A.

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951–1957.

Flys

, Nissley

D.V.

, Claasen

C.W.

Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192: 24–29.

Johnson

J.A.

, Li

J.F.

, Morris

Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192: 16–23.

Palmer

, Boltz

, Martinson

Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A 2006; 103: 7094–7099.

Martinson

N.A.

, Morris

, Gray

Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007; 44: 148–153.

Flys

T.S.

, Donnell

, Mwatha

Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195: 711–715.

10.

Jourdain

, Ngo-Giang-Huong

, Le Coeur

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351: 229–240.

11.

Coovadia

, Hunt

, Abrams

E.J.

Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48: 462–472.

12.

Lockman

, Hughes

, McIntyre

Lopinavir/ ritonavir versus nevirapine-based antiretroviral therapy in women with and without prior single-dose nevirapine use. N Engl J Med 2010; 363: 1499–1509.

13.

Boltz

V.F.

, Zheng

, Lockman

Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 2011; 108: 9202–9207.

14.

McIntyre

J.A.

, Hopley

, Moodley

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6: e1000172.

15.

World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Recommendations for a public health approach. Geneva: World Health Organization 2010.

16.

Halvas

E.K.

, Aldrovandi

G.M.

, Balfe

Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006; 44: 2612–2614.

17.

Palmer

, Boltz

, Maldarelli

Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 2006; 20: 701–710.

18.

Boltz

V.F.

, Maldarelli

, Martinson

Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods 2010; 164: 122–126.

19.

Palmer

, Kearney

, Maldarelli

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43: 406–413.

20.

Kearney

, Palmer

, Maldarelli

Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 2008; 22: 497–501.

21.

Gifford

R.J.

, Liu

T.F.

, Rhee

S.Y.

The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009; 25: 1197–1198.

22.

Johnson

J.A.

, Li

J.F.

, Wei

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5: e158.

23.

Simen

B.B.

, Simons

J.F.

, Hullsiek

K.H.

Low abundance drug-resistant viral variants in chronically infected HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199: 693–701.

24.

Paredes

, Lalama

C.M.

, Ribaudo

H.J.

Preexisting minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201: 662–671.

25.

Halvas

E.K.

, Wiegand

, Boltz

V.F.

Low frequency nonnucleoside reverse transcriptase inhibitor–resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010; 201: 672–680.

26.

Heneine

When do minority drug-resistant HIV-1 variants have a major clinical impact?

J Infect Dis 2010; 201: 647–649.

27.

Farr

S.L.

, Nelson

J.A.E.

, Ng'ombe

T.J.

Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr 2010; 54: 515–523.

28.

Lockman

, Shapiro

R.L.

, Smeaton

L.M.

Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356: 135–147.

29.

Rowley

C.F.

, Boutwell

C.L.

, Lee

E.J.

Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses 2010; 26: 293–300.